Vanguard Fiduciary Trust
RNAC icon

Vanguard Fiduciary Trust’s Cartesian Therapeutics RNAC Stock Holding History

Vanguard Fiduciary Trust’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Buy
91,854
+21,558
+31% +$160K ﹤0.01% 3044
2026
Q1 		$432K Buy
+70,296
New +$501K ﹤0.01% 3256

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust's RNAC Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cartesian Therapeutics (RNAC) stake by 31% in Q2 2026, buying an estimated $160K and bringing the position to 91,854 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

Vanguard Fiduciary Trust first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Vanguard Fiduciary Trust held 91,854 shares of Cartesian Therapeutics worth $957K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 21,558 Cartesian Therapeutics shares in Q2 2026, an estimated $160K.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3044 holding.
  • Vanguard Fiduciary Trust first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.